Clinical Interests

Sickle cell disease; hemoglobinopathies

Research Interests

Gene therapy strategies for sickle cell disease

MD: Northeastern Ohio Universities College of Medicine.

Residency: SUNY Upstate Medical University, Syracuse, New York.

Fellowship: Children’s Hospital of Los Angeles, Los Angeles, California and Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio.

Certification: Pediatrics: 2004; Pediatric Hematology Oncology: 2009

Perumbeti A, Malik P. Therapy for beta-globinopathies: a brief review and determinants for successful and safe correction.Ann N Y Acad Sci. 2010 Aug;1202:36-44. Review.

Perumbeti A, Malik P. Genetic correction of sickle cell anemia and beta-thalassemia: progress and new perspective.ScientificWorldJournal. 2010 Apr 13;10:644-54. Review.

Perumbeti A, Higashimoto T, Urbinati F, Franco R, Meiselman HJ, Witte D, Malik P. A novel human gamma-globin gene vector for genetic correction of sickle cell anemia in a humanized sickle mouse model: critical determinants for successful correction.Blood. 2009 Aug 6;114(6):1174-85.

Urbinati F, Arumugam P, Higashimoto T, Perumbeti A, Mitts K, Xia P, Malik P. Mechanism of reduction in titers from lentivirus vectors carrying large inserts in the 3'LTR.Mol Ther. 2009 Sep;17(9):1527-36.